The United States Food and Drug Administration (FDA) has granted approval to United States-based Viela Bio for its Breakthrough Therapy Designation of anti-CD19 monoclonal antibody inebilizumab, an investigational monotherapy for neuromyelitis optica spectrum disorder (NMOSD), a rare, life-threatening disease of the central nervous system, it was reported yesterday.
Breakthrough Therapy Designation is designed to accelerate the development and regulatory review of medicines aimed to treat a serious condition that have indicated encouraging early clinical results that may showcase substantial improvement on a clinically significant endpoint over available medicines.
The designation for the product is based on data from the pivotal N-MOmentum study assessing inebilizumab as monotherapy. The study enrolled 231 NMOSD patients for 6.5 months. The primary endpoint was time from initiation of treatment to an NMOSD attack.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval